Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant serplulimab with or without chemotherapy plus minimally invasive esophagectomy in elderly ESCC
ChiCTR2500111929Phase 2Recruiting
- Sponsor
- Shanghai Geriatric Medical Center
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of serplulimab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Shanghai Geriatric Medical Center. Primary endpoints: Objective response rate and Pathological complete response rate. Started Nov 2025; status: recruiting.
02
Drugs
serplulimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2500111929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500111929.